Ani Pharmaceuticals (ANIP) Net Cash Flow Growth (3y) (2013 - 2026)
Ani Pharmaceuticals (ANIP) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.06 Bn | 20.90 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.43 Bn | 18.62 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.81 Bn | 16.49 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -62.71% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 20.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.54% |
| Dec 31, 2025 | 71.25% |
| Sep 30, 2025 | 101.89% |
| Jun 30, 2025 | 90.98% |
| Mar 31, 2025 | 30.53% |
| Dec 31, 2024 | -85.27% |
| Sep 30, 2024 | -119.32% |
| Jun 30, 2024 | 153.01% |
| Mar 31, 2024 | -24.26% |
| Dec 31, 2023 | 68.62% |
| Sep 30, 2023 | 73.26% |
| Jun 30, 2023 | 134.47% |
| Mar 31, 2023 | 32.88% |
| Dec 31, 2022 | -71.26% |
| Sep 30, 2022 | -33.36% |
| Jun 30, 2022 | -97.61% |
| Mar 31, 2022 | -69.68% |
| Dec 31, 2021 | 327.02% |
| Sep 30, 2021 | 6.02% |
| Jun 30, 2021 | -31.38% |